# Crossject

Supergenerics / France

# No real news in the FY22 results.

Still some way to go... - 27/03/2023

## Change in EPS

U U	2023 : € -0.23 vs -0.33	ns	company and is deemed to constitute an acceptable min non-monetary benefit as defined in MiFID II
	2024 : € 0.49 vs 0.41	+20.8%	

We have updated our model after the release of the FY22 results. The latter were not meaningful (as usual) since the investment case is based on future product launches (hopefully as of FY24). Concerning our short-term earnings forecasts, they have been fine-tuned to factor in a slightly-higher contribution to revenues from the BARDA agreement signed last June. This is not a game changer in the short-term, but will still provide the group with an extra financing source in the current year and next.



# Fabrice FARIGOULE

pharma@alphavalue.eu +33 (0) 1 70 61 10 50 corporate.alphavalue.com

This research has been commissioned and paid for by the inor

Buy	Upside : 180%
Target Price (6 months)	€ 10.1
Share Price	€ 3.59
Market Cap. €M	130
Price Momentum	NEGATIVE
Extremes 12Months	1.71 🕨 4.95
Bloomberg	ALCJ FP Equity
Reuters	ALCJ.PA
Download Full Analysis	Company Page




PERF	1 w	1m	3m	12m
Crossject	-15.7%	-22.8%	3.16%	64.5%
Pharma	2.79%	-1.06%	0.98%	0.05%
SXXR Index	0.96%	-4.43%	3.49%	-0.32%

Last updated: 27/03/2023	12/22A	12/23E	12/24E	12/25E	
Adjusted P/E (x)	-8.07	-15.9	7.28	3.45	
Dividend yield (%)	0.00	0.00	0.00	0.00	
EV/EBITDA(R) (x)	-16.3	-25.2	4.89	2.72	
Adjusted EPS (€)	-0.35	-0.23	0.49	1.04	
Growth in EPS (%)	n/a	n/a	n/a	111	
Dividend (€)	0.00	0.00	0.00	0.00	
Sales (€M)	9.72	14.0	59.0	92.9	
EBIT margin (%)	0.00	0.00	78.0	100	
Attributable net profit (€M)	-11.2	-8.47	18.4	38.8	
ROE (after tax) (%)	798	703	407	114	
Gearing (%)	473		174	80.7	
Company Valuation - Company Financials					



### Sales by Geography



Consolidated P&L Accounts		12/22A	12/23E	12/24E
Sales	€M	9.72	14.0	59.0
Change in sales	%	43.5	44.2	32′
Change in staff costs	%	16.7	0.00	14.3
EBITDA	€M	-6.93	-5.59	34.
EBITDA(R) margin	%	-71.3	-39.9	58.
Depreciation	€M	-6.36	-6.36	-6.3
Underlying operating profit	€M	-13.3	-11.9	28.
Operating profit (EBIT)	€M	-13.3	-11.9	28.
Net financial expense	€M	-0.32	-0.70	-0.7
of which related to pensions	€M		0.00	0.0
Exceptional items & other	€M	0.23	0.00	0.0
Corporate tax	€M	2.22	4.17	-9.0
Equity associates	€M			
Minority interests	€M			
Adjusted attributable net profit	€M	-11.2	-8.47	18.
NOPAT	€M	-9.97	-8.96	21.
Cashflow Statement				
EBITDA	€M	-6.93	-5.59	34.
Change in WCR	€M	0.93	3.28	-48.
Actual div. received from equity holdi	€M	0.00	0.00	0.0
Paid taxes	€M		4.17	-9.0
Exceptional items	€M	0.00	0.00	0.0
Other operating cash flows	€M	0.00	0.00	0.0
Total operating cash flows	€M	-6.00	1.86	-23.
Capital expenditure	€M	-6.78	-2.27	-5.3
Total investment flows	€M	-6.78	-2.27	-5.3
Net interest expense	€M	-0.32	-0.70	-0.7
Dividends (parent company)	€M			
Dividends to minorities interests	€M	0.00	0.00	0.0
New shareholders' equity	€M	4.00	0.00	0.0
Total financial flows	€M	3.00	9.30	4.3
Change in cash position	€M	-9.78	8.90	-24.
Free cash flow (pre div.)	€M	-13.1	-1.10	-29.
Per Share Data				
No. of shares net of treas. stock (year	Mio	36.3	36.3	36.
Number of diluted shares (average)	Mio	31.4	37.4	37.
Benchmark EPS	€	-0.35	-0.23	0.4
Restated NAV per share	€			
Net dividend per share	€	0.00	0.00	0.0

### **Valuation Summary**

Benchmarks	Value	Weight
DCF	€ 12.0	40%
NAV/SOTP per share	€ 12.3	40%
P/E	€ 1.80	5%
EV/Ebitda	€ 2.55	5%
P/Book	€ 1.80	5%
Dividend Yield	€ 0.00	5%
TARGET PRICE	€ 10.1	100%

Largest comparables

- UCB
- Coloplast
- Faes Farma
- bioMerieux
- Hikma Pharmaceuti...
- Ipsen
- Carl Zeiss Meditec
  Sartorius
- , Sano

NAV/SOTP Calculation

Balance Sheet		12/22A	12/23E	12/24E
Goodwill	€M	0.00	0.00	0.00
Total intangible	€M	10.7	10.1	9.42
Tangible fixed assets	€M	7.67	5.16	5.77
Financial fixed assets	€M	0.00	0.00	0.00
WCR	€M	-2.64	-5.91	42.9
Other assets	€M	2.75	2.49	2.23
Total assets (net of short term liab.)	€M	19.1	12.5	60.9
Ordinary shareholders' equity	€M	2.69	-5.09	14.1
Quasi Equity & Preferred	€M			
Minority interests	€M			
Provisions for pensions	€M		0.00	0.00
Other provisions for risks and liabilities	€M	0.13	0.13	
Total provisions for risks and liabilities	€M	0.13	0.13	0.00
Tax liabilities	€M	0.00	0.00	0.00
Other liabilities	€M	7.48	7.48	7.48
Net debt (cash)	€M	8.86	9.96	39.3
Total liab. and shareholders' equity	€M	19.1	12.5	60.9
Capital Employed				
Capital employed after depreciation	€M	15.7	9.31	58.0
Profits & Risks Ratios				
ROE (after tax)	%	798	703	407
ROE (after tax) ROCE	% %	<b>798</b> -63.4	<b>703</b> -96.3	<b>407</b> 36.4
ROCE	%	-63.4		36.4
ROCE Gearing (at book value)	%	-63.4 <b>473</b>	-96.3	36.4 <b>174</b>
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R)	% % X	-63.4 473 -1.28	-96.3 -1.78	36.4 <b>174</b> 1.14
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x)	% % X	-63.4 473 -1.28	-96.3 -1.78	36.4 <b>174</b> 1.14
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios	% % X X	-63.4 473 -1.28 -41.7	-96.3 -1.78 -17.1	36.4 <b>174</b> 1.14 40.3
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark)	% % X X X	-63.4 473 -1.28 -41.7 -8.07	-96.3 -1.78 -17.1 -15.9	36.4 174 1.14 40.3 7.28
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield	% % X X X X	-63.4 473 -1.28 -41.7 -8.07 -12.6	-96.3 -1.78 -17.1 -15.9 -0.85	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7
ROCE      Gearing (at book value)      Adj. Net debt/EBITDA(R)      Interest cover (x)      Valuation Ratios      Reference P/E (benchmark)      Free cash flow yield      P/Book	% % X X X % X	-63.4 473 -1.28 -41.7 -41.7 -12.6 38.8	-96.3 -1.78 -17.1 -15.9 -0.85 -25.6	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7 9.17
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield	% % X X X % X	-63.4 473 -1.28 -41.7 -41.7 -12.6 38.8	-96.3 -1.78 -17.1 -15.9 -0.85 -25.6	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7 9.17
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation	% % X X % X %	-63.4 473 -1.28 -41.7 -12.6 38.8 0.00	-96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00	36.4 174 1.14 40.3 7.28 -22.7 9.17 0.00
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap	% % x x % x %	-63.4 473 -1.28 -41.7 -8.07 -12.6 38.8 0.00	-96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00	36.4 174 1.14 40.3 7.28 -22.7 9.17 0.00 130
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap + Provisions	% % X X % X % X %	-63.4 473 -1.28 -41.7 -8.07 -12.6 38.8 0.00 104 0.13	-96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00 130 0.13	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7 9.17 <b>0.00</b> 130 0.00
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap + Provisions + Unrecognised acturial losses/(gains)	% % X X % X % X % % \$ %	-63.4 473 -1.28 -41.7 -8.07 -12.6 38.8 0.00 104 0.13 0.00	-96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00 130 0.13 0.00	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7 9.17 <b>0.00</b> 130 0.00 0.00
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end	% % X X % X % X % % % % % % % % % % % %	-63.4 473 -1.28 -41.7 -12.6 38.8 0.00 104 0.13 0.00 8.86	-96.3 -96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00 130 0.13 0.00 9.96	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7 9.17 <b>0.00</b> 130 0.00 0.00 39.3
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent	% % X X % X % X % % € M € M € M € M € M	-63.4 473 -1.28 -41.7 -12.6 38.8 0.00 104 0.13 0.00 8.86	-96.3 -96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00 130 0.13 0.00 9.96	36.4 174 1.14 40.3 7.28 -22.7 9.17 0.00 130 0.00 39.3
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value)	% % X X % X % X % € M € M € M € M € M € M	-63.4 473 -1.28 -41.7 -12.6 38.8 0.00 104 0.13 0.00 8.86	-96.3 -96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00 130 0.13 0.00 9.96	36.4 174 1.14 40.3 7.28 -22.7 9.17 0.00 130 0.00 39.3
ROCE Gearing (at book value) Adj. Net debt/EBITDA(R) Interest cover (x) Valuation Ratios Reference P/E (benchmark) Free cash flow yield P/Book Dividend yield EV Calculation Market cap + Provisions + Unrecognised acturial losses/(gains) + Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value) + Minority interests (fair value)	% % x x % x % x % % x % % % % % % % % %	-63.4 473 -1.28 -41.7 -12.6 38.8 0.00 104 0.13 0.00 8.86 0.00	-96.3 -96.3 -1.78 -17.1 -15.9 -0.85 -25.6 0.00 130 0.13 0.00 9.96 0.00	36.4 <b>174</b> 1.14 40.3 <b>7.28</b> -22.7 9.17 <b>0.00</b> 130 0.00 0.00 39.3 0.00

Analyst : Fabrice Farigoule, Changes to Forecasts : 27/03/2023.

© 2023, AlphaValue All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by those methods and procedures. All opinions and estimates included herein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein has been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information net inselading at the time of publication, we make no representation that it is accurate or completed not and it should not be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.